Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Blood Protein Helps Create 3D Nanofiber Scaffolds

It has been well established that there are a variety of plasma proteins playing essential roles in the wound healing process. Yet, the ability for using these molecules in a clinical capacity has been limited. Although now, investigators at the University of

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

It has been well established that there are a variety of plasma proteins playing essential roles in the wound healing process. Yet, the ability for using these molecules in a clinical capacity has been limited. Although now, investigators at the University of Bremen, Germany, have employed a plasma protein found in blood to develop a new method for making wound-healing tissue scaffolds. The research team’s new scaffold can be attached or detached from a surface, for either in vitro laboratory tissue studies or direct applications in the body.

“The protein we used is called fibrinogen,” explained senior study investigator Dorothea Brüggemann, PhD, a professor and group lead at the institute for biophysics within the University of Bremen. “It is an extracellular glycoprotein found in blood plasma and plays a major role in wound healing by assembling into a fibrous network to form a provisional extracellular matrix (ECM) that helps with wound closure.”

Findings from the new study were published recently in Biofabrication through an article titled “Fabrication of 3D-nanofibrous fibrinogen scaffolds using salt-induced self-assembly.”

Due to its versatile molecular interactions, fibrinogen is often processed into hydrogels and fibrous scaffolds for cell culture and tissue engineering applications in vitro. However, existing ways of doing this—such as electrospinning or the preparation of fibrin hydrogels—use organic solvents, high electric fields, or enzymatic activity, which change the molecular structures or native protein functions of fibrinogen.

To solve this, the team wanted to find out if they could develop a simple and well-controllable way to make three-dimensional scaffolds while retaining fibrinogen’s properties.

“We introduced a novel biofabrication technique to prepare three-dimensional, nanofibrous fibrinogen scaffolds by salt-induced self-assembly. For the first time, we were able to fabricate either free-standing or immobilized fibrinogen scaffolds on demand by tailoring the underlying substrate material and adding a fixation and washing procedure after the fiber assembly,” the authors wrote. “Using scanning electron microscopy, we observed that different buffers including phosphate buffered saline and sodium phosphate reproducibly yielded dense fiber networks on bare and silanized glass surfaces, gold as well as polystyrene upon drying. Fibrillogenesis could be induced with a fibrinogen concentration of at least 2 mg ml−1 in a pH regime of 7–9. Fiber diameters ranged from 100 to 300 nm, thus resembling native fibrin and ECM protein fibers.”

“For the first time, we were able to assemble fibrinogen into dense, three-dimensional scaffolds without using high voltages, organic solvents, or enzymatic activity,” Brüggemann added. “Our biofabrication process can be controlled simply by adjusting the fibrinogen and salt concentration, and the pH range.”

The dimensions of the scaffolds reached diameters in the centimeter range and a thickness of several micrometers. With 100 to 300 nm, the diameters of self-assembled fibers were in the range of native protein fibers.

“By adjusting the salt concentration, we could prepare fibrinogen scaffolds with overall dimensions in the centimeter range and a thickness of 3 to 5 μm,” the authors penned. “Using FTIR analysis we observed peak shifts of the amide bands for fibrinogen nanofibers in comparison to planar fibrinogen, which indicates changes in the secondary structure. Since fibrillogenesis was only induced upon drying when salt ions were present, we assume that protein molecules were locally oriented in the respective buffers, which—in combination with the observed conformational changes—led to the assembly of individual molecules into fibers.”

The research team was excited by their findings and are looking ahead toward potential applications and increased testing on a variety of wounds and patient groups.

“This novel class of fibrinogen nanofibers holds great potential for various biomedical applications,” Brüggemann concluded. “For example, in future studies on blood coagulation, our immobilized fibrinogen nanofibers could provide a valuable in vitro platform for initial drug screening. On novel wound healing applications, it will be highly interesting to study the interaction of fibroblasts and keratinocytes with our free-standing fibrinogen scaffolds.”

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
02Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →